ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0746

Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial

Ho SO1, Evelyn Chow2, Isaac Cheng1, Xerox Lau2, Tena Li1, Cheuk Chun Szeto2 and Lai-shan Tam1, 1The Chinese University of Hong Kong, Hong Kong, China, 2The Chinese University of Hong Kong, Hong Kong, Hong Kong

Meeting: ACR Convergence 2022

Keywords: clinical trial, Cost-Effectiveness, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Health Services Research Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: During the pandemic, vulnerable patients such as those with lupus nephritis (LN) faced the difficult choice between COVID-19 infection risk during a clinic visit and postponing the needed care. An option would be to adopt telemedicine (TM). Despite being widely adopted, the evidence supporting the use of TM in rheumatology has been limited. Thus, we conducted a pragmatic trial comparing Telemedicine and standard in-person follow-up (FU) in patients with LN (“Tele-LN”). We primarily aimed to evaluate the effectiveness to maintain disease activity control using TM compared to conventional in-person outpatient FU. The secondary objectives were to compare the patient reported outcomes, safety and cost-of-illness between the 2 modes of health care delivery.

Methods: This was a 1-year, randomized controlled trial conducted at a regional hospital in Hong Kong. From 5/2020, patients with a diagnosis of SLE according to the 2019 EULAR/ACR classification criteria followed up at the LN clinic were invited to participate. Patients needed to possess the technology for conducting a TM visit. Participants were randomized 1:1 to either TM (TM group) or standard FU (SF group). Patients randomized to receive TM FU were scheduled for real-time video consultations. Patients in the SF group received standard in-person outpatient care. An in-person clinic consultation could be arranged as requested by the patients or clinicians. Similarly, a TM consultation could be arranged as required.

Results: At the end of the study (12/2021), 70 patients in the TM group and 71 patients in the SF completed one-year FU (Figure 1). There were no baseline differences between the 2 groups Table 1. The results with respect to the primary and major secondary end points are provided in Table 2. At 1 year, similar proportion of patients in the TM group and SF group were in lupus low disease activity state (LLDAS) or remission. SLE disease activity indices including SLEDAI-2k, PGA, proteinuria amount and serum anti-ds-DNA level remained similar between the 2 groups. There were no differences in the SF-36, lupusQoL and HADS scores between the 2 groups except a slightly higher HAQ in the TM group at the end of the study. The overall patient satisfaction score was higher in the TM group. At the end of the study, 67.9% of the overall participants agreed to use TM as a mode of future FU. Although the mean indirect costs of illness were numerically higher in the SF group, the out-of-pocket costs for health care services other than those provided by the public sector were similar between the two groups. The total number of FU was similar in the 2 groups. However, significantly more patients in the TM group requested change mode of FU. The proportion of patients requiring hospitalization was also higher in the TM group. Not being in LLDAS at baseline was the independent predictor of hospitalization (OR 3.4, 95%CI 1.20-9.65). None of the participants has been tested positive for COVID-19 throughout the study.

Conclusion: The results of the study suggest that TM delivered care could help maintaining disease control and psychosocial wellbeing during the pandemic, but it needs to be complemented by physical visits as required, particularly in those with unstable disease.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: H. SO, None; E. Chow, None; I. Cheng, None; X. Lau, None; T. Li, None; C. Szeto, None; L. Tam, AbbVie, Amgen, Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKlein(GSK), Janssen, Novartis, Pfizer, Sanofi, AstraZeneca.

To cite this abstract in AMA style:

SO H, Chow E, Cheng I, Lau X, Li T, Szeto C, Tam L. Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/telemedicine-for-follow-up-of-lupus-nephritis-in-the-covid-19-outbreak-a-pragmatic-randomized-controlled-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/telemedicine-for-follow-up-of-lupus-nephritis-in-the-covid-19-outbreak-a-pragmatic-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology